← Back to Search

Topical Retinoid and Benzoyl Peroxide Combination

IDP-126 Gel for Acne

Phase 2
Waitlist Available
Research Sponsored by Bausch Health Americas, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Screening 3 weeks
Treatment Varies
Follow Up baseline to week 12
Awards & highlights


This study is evaluating whether a gel containing a new medication may help treat acne.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to week 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to week 12 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Absolute change from Baseline to Week 12 in lesion counts.
Percentage of subjects who achieve at least a two-grade reduction from baseline and are "Clear" or "Almost Clear" at Week 12 in the Evaluator's Global Severity Score.

Side effects data

From 2021 Phase 3 trial • 183 Patients • NCT04214639
Application site pain
Study treatment Arm
IDP-126 Gel
IDP-126 Vehicle Gel

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: IDP-126 GelExperimental Treatment1 Intervention
Group II: Epiduo® Forte GelActive Control1 Intervention
Group III: IDP-126 Vehicle GelPlacebo Group1 Intervention
First Studied
Drug Approval Stage
How many patients have taken this drug
IDP-126 Gel
Completed Phase 3

Find a Location

Who is running the clinical trial?

Bausch Health Americas, Inc.Lead Sponsor
262 Previous Clinical Trials
81,342 Total Patients Enrolled
7 Trials studying Acne
2,298 Patients Enrolled for Acne
Anya LoncaricStudy DirectorBausch Health Americas, Inc.
39 Previous Clinical Trials
19,977 Total Patients Enrolled
3 Trials studying Acne
88 Patients Enrolled for Acne
Varsha BhattStudy DirectorBausch Health Americas, Inc.
8 Previous Clinical Trials
353 Total Patients Enrolled
~168 spots leftby Jul 2025